https://orcid.org/0000-0001-9893-5856
Abstract
Drug resistance and intolerance of dolutegravir-containing antiretroviral therapy (ART) are rising in low- and middle-income countries, resulting in a potentially increased use of doravirine-containing ART use. There are knowledge gaps regarding doravirine and hormonal contraceptive drug-drug interactions among women living with HIV (WLWH).
We conducted a five parallel group, prospective pharmacokinetic study among WLWH aged 18-45 years in Johannesburg, South Africa between November 2021 and February 2024. We included a sixth, historical comparator group from a Kenyan study. After a ≥6-week lead-in period with doravirine-containing ART, participants initiated injectable medroxyprogesterone acetate (MPA), implantable etonogestrel (ENG), or non-hormonal intrauterine device contraception and were observed every 2-4 weeks for an additional 12 or 24 weeks. We analyzed serum MPA and ENG and plasma doravirine or dolutegravir concentrations per visit, using validated liquid chromatography–mass spectrometry (LC-MS/MS) assays. We assessed log-transformed concentrations of each drug with geometric mean ratios (GMR; 90% confidence intervals) and a multivariate model adjusted for age and body mass index. We described safety, tolerability, and effectiveness (HIV viral load <40 copies/mL) of doravirine-containing ART.
A total of 128 participants are included in this analysis. There were no significant reductions in the MPA, ENG, or doravirine concentrations. A total of 8 (3%) adverse events grade 2 or higher were considered attributable to doravirine-containing ART and 22 (8%) to the contraceptive method. ART satisfaction was 100%, and viral suppression at study exit ranged from 86-96%.
We found no detrimental bidirectional drug-drug interactions and few adverse events between doravirine and hormonal contraceptives.
Accepted manuscripts
